Valuation: Delcath Systems, Inc.

Market Cap 447M 391M 361M 337M 635M 42.27B 650M 4.35B 1.68B 20.85B 1.68B 1.64B 72.39B P/E 2026 *
-22.8x
P/E 2027 * -24x
Enterprise Value 447M 391M 361M 337M 635M 42.27B 650M 4.35B 1.68B 20.85B 1.68B 1.64B 72.39B EV / Sales 2026 *
4.33x
EV / Sales 2027 * 3.42x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+5.11%+4.25%-25.63% 21.07B
+0.29%-0.57%-19.12%-19.73% 14.03B
+0.55%+7.95%-59.47%-46.85% 5.45B
+0.10%+2.77% - - 3.79B
-1.13%+1.35%-21.49%-18.20% 1.73B
-3.77%-2.07%+17.24%-9.24% 1.5B
+3.14%-3.36%-45.80%-67.78% 1.06B
+0.85%+0.51%+39.91%+97.35% 704M
+5.17%-24.54% - - 322M
Average +0.76%-0.51%-12.07%-12.87% 5.52B
Weighted average by Cap. +0.64%+1.09%-11.74%-24.61%

Financials

2026 *2027 *
Net sales 103M 90.4M 83.46M 77.93M 147M 9.76B 150M 1B 388M 4.82B 388M 379M 16.72B 131M 114M 106M 98.6M 186M 12.35B 190M 1.27B 491M 6.09B 491M 480M 21.15B
Net income -21.04M -18.43M -17.01M -15.89M -29.9M -1.99B -30.58M -205M -79.03M -982M -79.03M -77.3M -3.41B -20M -17.51M -16.17M -15.1M -28.42M -1.89B -29.07M -195M -75.12M -933M -75.12M -73.47M -3.24B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-